NASDAQ:ABMDABIOMED Stock Price, Forecast & News

ABIOMED's stock was trading at $151.13 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ABMD stock has increased by 75.8% and is now trading at $265.68. View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ABIOMED in the last year. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for ABIOMED.

ABIOMED is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for ABIOMED.

ABIOMED, Inc. (NASDAQ:ABMD) released its earnings results on Thursday, April, 30th. The medical equipment provider reported $0.70 EPS for the quarter, missing analysts' consensus estimates of $0.96 by $0.26. The medical equipment provider had revenue of $206.66 million for the quarter, compared to analyst estimates of $209.58 million. ABIOMED had a net margin of 24.14% and a return on equity of 18.51%. The company's revenue for the quarter was down .2% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.60 EPS. View ABIOMED's earnings history.

8 brokerages have issued twelve-month target prices for ABIOMED's stock. Their forecasts range from $152.00 to $240.00. On average, they expect ABIOMED's stock price to reach $193.00 in the next twelve months. This suggests that the stock has a possible downside of 27.4%. View analysts' price targets for ABIOMED.

Media headlines about ABMD stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. ABIOMED earned a media sentiment score of -1.5 on InfoTrie's scale. They also gave press coverage about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about ABIOMED.

ABIOMED saw a decline in short interest during the month of June. As of June 30th, there was short interest totaling 2,360,000 shares, a decline of 13.6% from the June 15th total of 2,730,000 shares. Based on an average daily trading volume, of 559,700 shares, the short-interest ratio is presently 4.2 days. Approximately 5.4% of the shares of the stock are sold short. View ABIOMED's Current Options Chain.

Some companies that are related to ABIOMED include Abbott Laboratories (ABT), Medtronic (MDT), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Stryker (SYK), Boston Scientific (BSX), Baxter International (BAX), Edwards Lifesciences (EW), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Insulet (PODD) and Masimo (MASI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ABIOMED investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Align Technology (ALGN), Netflix (NFLX), Arista Networks (ANET), Square (SQ), Paypal (PYPL), salesforce.com (CRM) and Adobe (ADBE).

ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."

ABIOMED's stock is owned by many different retail and institutional investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.02%), State of Alaska Department of Revenue (0.02%), Legacy Capital Partners Inc. (0.01%), Contravisory Investment Management Inc. (0.00%), Cypress Capital Group (0.00%) and IBM Retirement Fund (0.00%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Martin P Sutter and Michael G Howley. View institutional ownership trends for ABIOMED.

ABMD stock was acquired by a variety of institutional investors in the last quarter, including Legacy Capital Partners Inc., Envestnet Asset Management Inc., Contravisory Investment Management Inc., Cypress Capital Group, IBM Retirement Fund, and State of Alaska Department of Revenue. View insider buying and selling activity for ABIOMED.

Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ABMD stock can currently be purchased for approximately $265.68.

ABIOMED has a market capitalization of $11.97 billion and generates $840.88 million in revenue each year. The medical equipment provider earns $203.01 million in net income (profit) each year or $4.74 on an earnings per share basis. ABIOMED employs 1,536 workers across the globe.

The official website for ABIOMED is www.abiomed.com.

ABIOMED's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected]